 [1m([0morchestrator-aplastic anemia-LISINOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LISINOPRIL increase or decrease the risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-LISINOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-LISINOPRIL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-aplastic anemia-LISINOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does LISINOPRIL increase the risk of aplastic anemia?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-LISINOPRIL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes LISINOPRIL increase the risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-LISINOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-LISINOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-LISINOPRIL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LISINOPRIL increase the risk of aplastic anemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does LISINOPRIL increase the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"LISINOPRIL"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: LISINOPRIL: adverse_reactions: Angioedema: Angioedema has been reported in patients receiving PRINZIDE, with an incidence higher in Black than in non-Black patients. Angioedema associated [0m
[31mwith laryngeal edema may be fatal. If angioedema of the face, extremities, lips, tongue, glottis and/or larynx occurs, treatment with PRINZIDE should be discontinued and appropriate therapy instituted[0m
[31mimmediately. In rare cases, intestinal angioedema has been reported with angiotensin converting enzyme inhibitors including lisinopril. [0m[1;31m([0m[31mSee WARNINGS [0m[1;31m)[0m[31m. Hypotension: In clinical trials, adverse [0m
[31meffects relating to hypotension occurred as follows: hypotension [0m[1;31m([0m[1;31m1.4[0m[31m percent[0m[1;31m)[0m[31m, orthostatic hypotension [0m[1;31m([0m[1;31m0.5[0m[31m percent[0m[1;31m)[0m[31m, other orthostatic effects [0m[1;31m([0m[1;31m3.2[0m[31m percent[0m[1;31m)[0m[31m. In addition syncope occurred in [0m[1;31m0.8[0m[31m [0m
[31mpercent of patients [0m[1;31m([0m[31mSee WARNINGS [0m[1;31m)[0m[31m. LISINOPRIL: adverse_reactions: Cough: See PRECAUTIONS - Cough . Clinical Laboratory Test Findings Serum Electrolytes: [0m[1;31m([0m[31mSee PRECAUTIONS [0m[1;31m)[0m[31m. Creatinine, Blood Urea [0m
[31mNitrogen: Minor reversible increases in blood urea nitrogen and serum creatinine were observed in patients with essential hypertension treated with lisinopril and hydrochlorothiazide tablets. More [0m
[31mmarked increases have also been reported and were more likely to occur in patients with renal artery stenosis [0m[1;31m([0m[31mSee PRECAUTIONS [0m[1;31m)[0m[31m. Serum Uric Acid, Glucose, Magnesium, Cholesterol, Triglycerides and [0m
[31mCalcium: [0m[1;31m([0m[31mSee PRECAUTIONS [0m[1;31m)[0m[31m. Hemoglobin and Hematocrit: Small decreases in hemoglobin and hematocrit [0m[1;31m([0m[31mmean decreases of approximately [0m[1;31m0.5[0m[31m g% and [0m[1;31m1.5[0m[31m vol%, respectively[0m[1;31m)[0m[31m occurred frequently in [0m
[31mhypertensive patients treated with lisinopril and hydrochlorothiazide tablets but were rarely of clinical importance unless another cause of anemia coexisted. LISINOPRIL: adverse_reactions: In [0m
[31mclinical trials, [0m[1;31m0.4[0m[31m% of patients discontinued therapy due to anemia. Liver Function Tests: Rarely, elevations of liver enzymes and/or serum bilirubin have occurred. [0m[1;31m([0m[31mSee WARNINGS, Hepatic Failure [0m[1;31m)[0m[31m. [0m
[31mOther adverse reactions that have been reported with the individual components are listed below: Lisinopril - In clinical trials adverse reactions which occurred with lisinopril were also seen with [0m
[31mlisinopril and hydrochlorothiazide tablets. LISINOPRIL: adverse_reactions: In addition, and since lisinopril has been marketed, the following adverse reactions have been reported with lisinopril and [0m
[31mshould be considered potential adverse reactions for lisinopril and hydrochlorothiazide tablets: Body as a Whole: Anaphylactoid reactions [0m[1;31m([0m[31msee WARNINGS, Anaphylactoid and Possibly Related Reactions [0m[1;31m)[0m[31m,[0m
[31mmalaise, edema, facial edema, pain, pelvic pain, flank pain, chills; Cardiovascular: Cardiac arrest, myocardial infarction or cerebrovascular accident, possibly secondary to excessive hypotension in [0m
[31mhigh risk patients [0m[1;31m([0m[31msee WARNINGS, Hypotension [0m[1;31m)[0m[31m, pulmonary embolism and infarction, worsening of heart failure, arrhythmias [0m[1;31m([0m[31mincluding tachycardia, ventricular tachycardia, atrial tachycardia, atrial [0m
[31mfibrillation, bradycardia, and premature ventricular contractions[0m[1;31m)[0m[31m, angina pectoris, transient ischemic attacks LISINOPRIL: adverse_reactions: , paroxysmal nocturnal dyspnea, decreased blood pressure,[0m
[31mperipheral edema, vasculitis; Digestive: Pancreatitis, hepatitis [0m[1;31m([0m[31mhepatocellular or cholestatic jaundice[0m[1;31m)[0m[31m [0m[1;31m([0m[31msee WARNINGS, Hepatic Failure [0m[1;31m)[0m[31m, gastritis, anorexia, flatulence, increased salivation; [0m
[31mEndocrine: Diabetes mellitus, syndrome of inappropriate antidiuretic hormone secretion [0m[1;31m([0m[31mSIADH[0m[1;31m)[0m[31m; Hematologic: Rare cases of neutropenia, thrombocytopenia, and bone marrow depression have been reported.[0m
[31mLISINOPRIL: adverse_reactions: Hemolytic anemia has been reported; a causal relationship to lisinopril cannot be excluded; Metabolic: Gout, weight loss, dehydration, fluid overload, weight gain; [0m
[31mMusculoskeletal: Arthritis, arthralgia, neck pain, hip pain, joint pain, leg pain, arm pain, lumbago; Nervous System/Psychiatric: Ataxia, memory impairment, tremor, insomnia, stroke, nervousness, [0m
[31mconfusion, peripheral neuropathy [0m[1;31m([0m[31me.g. LISINOPRIL: adverse_reactions: paresthesia, dysesthesia[0m[1;31m)[0m[31m, spasm, hypersomnia, irritability, mood alterations [0m[1;31m([0m[31mincluding depressive symptoms[0m[1;31m)[0m[31m; hallucinations ; [0m
[31mRespiratory: Malignant lung neoplasms, hemoptysis, pulmonary edema, pulmonary infiltrates, eosinophilic pneumonitis, bronchospasm, asthma, pleural effusion, pneumonia, wheezing, orthopnea, painful [0m
[31mrespiration, epistaxis, laryngitis, sinusitis, pharyngitis, rhinitis, rhinorrhea, chest sound abnormalities; Skin: Urticaria, alopecia, herpes zoster, photosensitivity, skin lesions, skin infections, [0m
[31mpemphigus, erythema, psoriasis. LISINOPRIL: adverse_reactions: Other severe skin reactions [0m[1;31m([0m[31mincluding toxic epidermal necrolysis, Stevens-Johnson syndrome and cutaneous pseudolymphoma[0m[1;31m)[0m[31m have been [0m
[31mreported rarely; causal relationship has not been established; Special Senses: Visual loss, diplopia, photophobia, taste disturbances, olfactory disturbances; Urogenital: Acute renal failure, [0m
[31moliguria, anuria, uremia, progressive azotemia, renal dysfunction [0m[1;31m([0m[31msee PRECAUTIONS and DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m, pyelonephritis, dysuria, breast pain. Miscellaneous: A symptom complex has been [0m
[31mreported which may include a positive ANA, an elevated erythrocyte sedimentation rate, arthralgia/arthritis, myalgia, fever, vasculitis, leukocytosis, eosinophilia, photosensitivity, rash, and other [0m
[31mdermatological manifestations. LISINOPRIL: adverse_reactions: Fetal/Neonatal Morbidity and Mortality: See WARNINGS , Pregnancy, Lisinopril, Fetal/Neonatal Morbidity and Mortality . LISINOPRIL: [0m
[31madverse_reactions: Hydrochlorothiazide - Body as a Whole: Weakness; Digestive: Anorexia, gastric irritation, cramping, jaundice [0m[1;31m([0m[31mintrahepatic cholestatic jaundice[0m[1;31m)[0m[31m [0m[1;31m([0m[31mSee WARNINGS, Hepatic Failure [0m[1;31m)[0m[31m, [0m
[31mpancreatitis, sialadenitis, constipation; Hematologic: Leukopenia, agranulocytosis, thrombocytopenia, aplastic anemia, hemolytic anemia; Musculoskeletal: Muscle spasm; Nervous System/Psychiatric: [0m
[31mRestlessness; Renal: Renal failure, renal dysfunction, interstitial nephritis [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m; Skin: Erythema multiforme including Stevens-Johnson syndrome, exfoliative dermatitis including toxic [0m
[31mepidermal necrolysis, alopecia; Special Senses: Xanthopsia; Hypersensitivity: Purpura, photosensitivity, urticaria, necrotizing angiitis [0m[1;31m([0m[31m LISINOPRIL: adverse_reactions: vasculitis and cutaneous [0m
[31mvasculitis[0m[1;31m)[0m[31m, respiratory distress including pneumonitis and pulmonary edema, anaphylactic reactions. Non-melanoma Skin Cancer Hydrochlorothiazide is associated with an increased risk of non-melanoma [0m
[31mskin cancer. In a study conducted in the Sentinel System, increased risk was predominantly for squamous cell carcinoma [0m[1;31m([0m[31mSCC[0m[1;31m)[0m[31m and in white patients taking large cumulative doses. The increased risk for[0m
[31mSCC in the overall population was approximately [0m[1;31m1[0m[31m additional case per [0m[1;31m16[0m[31m,[0m[1;31m000[0m[31m patients per year, and for white patients taking a cumulative dose of ≥[0m[1;31m50[0m[31m,[0m[1;31m000[0m[31m mg the risk increase was approximately [0m[1;31m1[0m[31m [0m
[31madditional SCC case for every [0m[1;31m6[0m[31m,[0m[1;31m700[0m[31m patients per year.         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: LISINOPRIL: clinical_pharmacology: Lisinopril absorption is not influenced by the presence of food in the gastrointestinal tract. Upon multiple dosing, lisinopril exhibits an effective [0m
[31mhalf-life of accumulation of [0m[1;31m12[0m[31m hours. Impaired renal function decreases elimination of lisinopril, which is excreted principally through the kidneys, but this decrease becomes clinically important [0m
[31monly when the glomerular filtration rate is below [0m[1;31m30[0m[31m mL/min. Above this glomerular filtration rate, the elimination half-life is little changed. With greater impairment, however, peak and trough [0m
[31mlisinopril levels increase, time to peak concentration increases and time to attain steady state is prolonged. Older patients, on average, have [0m[1;31m([0m[31mapproximately doubled[0m[1;31m)[0m[31m higher blood levels and area [0m
[31munder the plasma concentration time curve [0m[1;31m([0m[31mAUC[0m[1;31m)[0m[31m than younger patients. [0m[1;31m([0m[31mSee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m Lisinopril can be removed by hemodialysis. Studies in rats indicate that lisinopril crosses the [0m
[31mblood-brain barrier poorly. LISINOPRIL: clinical_pharmacology: Multiple doses of lisinopril in rats do not result in accumulation in any tissues. However, milk of lactating rats contains radioactivity[0m
[31mfollowing administration of [0m[1;31m14[0m[31m C lisinopril. By whole body autoradiography, radioactivity was found in the placenta following administration of labeled drug to pregnant rats, but none was found in the[0m
[31mfetuses. Pharmacodynamics Administration of lisinopril to patients with hypertension results in a reduction of supine and standing blood pressure to about the same extent with no compensatory [0m
[31mtachycardia. Symptomatic postural hypotension is usually not observed although it can occur and should be anticipated in volume and/or salt-depleted patients. [0m[1;31m([0m[31mSee WARNINGS .[0m[1;31m)[0m[31m In most patients [0m
[31mstudied, onset of antihypertensive activity was seen at one hour after oral administration of an individual dose of lisinopril, with peak reduction of blood pressure achieved by six hours. LISINOPRIL:[0m
[31mclinical_pharmacology: In some patients achievement of optimal blood pressure reduction may require two to four weeks of therapy. At recommended single daily doses, antihypertensive effects have been [0m
[31mmaintained for at least [0m[1;31m24[0m[31m hours, after dosing, although the effect at [0m[1;31m24[0m[31m hours was substantially smaller than the effect six hours after dosing. The antihypertensive effects of lisinopril have [0m
[31mcontinued during long-term therapy. Abrupt withdrawal of lisinopril has not been associated with a rapid increase in blood pressure; nor with a significant overshoot of pretreatment blood pressure. In[0m
[31mhemodynamic studies in patients with essential hypertension, blood pressure reduction was accompanied by a reduction in peripheral arterial resistance with little or no change in cardiac output and in[0m
[31mheart rate. In a study in nine hypertensive patients, following administration of lisinopril, there was an increase in mean renal blood flow that was not significant. LISINOPRIL: [0m
[31mclinical_pharmacology: Data from several small studies are inconsistent with respect to the effect of lisinopril on glomerular filtration rate in hypertensive patients with normal renal function, but [0m
[31msuggest that changes, if any, are not large. In patients with renovascular hypertension lisinopril has been shown to be well tolerated and effective in controlling blood pressure [0m[1;31m([0m[31msee PRECAUTIONS [0m[1;31m)[0m[31m. [0m
[31mHydrochlorothiazide The mechanism of the antihypertensive effect of thiazides is unknown. Thiazides do not usually affect normal blood pressure. Hydrochlorothiazide is a diuretic and antihypertensive.[0m
[31mIt affects the distal renal tubular mechanism of electrolyte reabsorption. Hydrochlorothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be [0m
[31maccompanied by some loss of potassium and bicarbonate. After oral use diuresis begins within two hours, peaks in about four hours and lasts about [0m[1;31m6[0m[31m to [0m[1;31m12[0m[31m hours. LISINOPRIL: clinical_pharmacology: [0m
[31mHydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. When plasma levels have been followed for at least [0m[1;31m24[0m[31m hours, the plasma half-life has been observed to vary between [0m[1;31m5.6[0m[31m [0m
[31mand [0m[1;31m14.8[0m[31m hours. At least [0m[1;31m61[0m[31m percent of the oral dose is eliminated unchanged within [0m[1;31m24[0m[31m hours. Hydrochlorothiazide crosses the placental but not the blood-brain barrier.         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: LISINOPRIL: openfda: spl_set_id         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: LISINOPRIL: pharmacokinetics: Pharmacokinetics and Metabolism Following oral administration of lisinopril, peak serum concentrations occur within about [0m[1;31m7[0m[31m hours. Declining serum concentrations[0m
[31mexhibit a prolonged terminal phase which does not contribute to drug accumulation. This terminal phase probably represents saturable binding to ACE and is not proportional to dose. Lisinopril does not[0m
[31mappear to be bound to other serum proteins. Lisinopril does not undergo metabolism and is excreted unchanged entirely in the urine. Based on urinary recovery, the mean extent of absorption of [0m
[31mlisinopril is approximately [0m[1;31m25[0m[31m percent, with large intersubject variability [0m[1;31m([0m[1;31m6[0m[31m% to [0m[1;31m60[0m[31m%[0m[1;31m)[0m[31m at all doses tested [0m[1;31m([0m[1;31m5[0m[31m mg to [0m[1;31m80[0m[31m mg[0m[1;31m)[0m[31m. Lisinopril absorption is not influenced by the presence of food in the [0m
[31mgastrointestinal tract. Upon multiple dosing, lisinopril exhibits an effective half-life of accumulation of [0m[1;31m12[0m[31m hours. LISINOPRIL: pharmacokinetics: Impaired renal function decreases elimination of [0m
[31mlisinopril, which is excreted principally through the kidneys, but this decrease becomes clinically important only when the glomerular filtration rate is below [0m[1;31m30[0m[31m mL/min. Above this glomerular [0m
[31mfiltration rate, the elimination half-life is little changed. With greater impairment, however, peak and trough lisinopril levels increase, time to peak concentration increases and time to attain [0m
[31msteady state is prolonged. Older patients, on average, have [0m[1;31m([0m[31mapproximately doubled[0m[1;31m)[0m[31m higher blood levels and area under the plasma concentration time curve [0m[1;31m([0m[31mAUC[0m[1;31m)[0m[31m than younger patients. [0m[1;31m([0m[31mSee DOSAGE AND [0m
[31mADMINISTRATION [0m[1;31m)[0m[31m Lisinopril can be removed by hemodialysis. Studies in rats indicate that lisinopril crosses the blood-brain barrier poorly. Multiple doses of lisinopril in rats do not result in [0m
[31maccumulation in any tissues. However, milk of lactating rats contains radioactivity following administration of [0m[1;31m14[0m[31m C lisinopril. LISINOPRIL: pharmacokinetics: By whole body autoradiography, [0m
[31mradioactivity was found in the placenta following administration of labeled drug to pregnant rats, but none was found in the fetuses.         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: LISINOPRIL: pharmacodynamics: Pharmacodynamics Administration of lisinopril to patients with hypertension results in a reduction of supine and standing blood pressure to about the same extent[0m
[31mwith no compensatory tachycardia. Symptomatic postural hypotension is usually not observed although it can occur and should be anticipated in volume and/or salt-depleted patients. [0m[1;31m([0m[31mSee WARNINGS .[0m[1;31m)[0m[31m In [0m
[31mmost patients studied, onset of antihypertensive activity was seen at one hour after oral administration of an individual dose of lisinopril, with peak reduction of blood pressure achieved by six [0m
[31mhours. In some patients achievement of optimal blood pressure reduction may require two to four weeks of therapy. At recommended single daily doses, antihypertensive effects have been maintained for [0m
[31mat least [0m[1;31m24[0m[31m hours, after dosing, although the effect at [0m[1;31m24[0m[31m hours was substantially smaller than the effect six hours after dosing. The antihypertensive effects of lisinopril have continued during [0m
[31mlong-term therapy. LISINOPRIL: pharmacodynamics: Abrupt withdrawal of lisinopril has not been associated with a rapid increase in blood pressure; nor with a significant overshoot of pretreatment blood[0m
[31mpressure. In hemodynamic studies in patients with essential hypertension, blood pressure reduction was accompanied by a reduction in peripheral arterial resistance with little or no change in cardiac [0m
[31moutput and in heart rate. In a study in nine hypertensive patients, following administration of lisinopril, there was an increase in mean renal blood flow that was not significant. Data from several [0m
[31msmall studies are inconsistent with respect to the effect of lisinopril on glomerular filtration rate in hypertensive patients with normal renal function, but suggest that changes, if any, are not [0m
[31mlarge. In patients with renovascular hypertension lisinopril has been shown to be well tolerated and effective in controlling blood pressure [0m[1;31m([0m[31msee PRECAUTIONS [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: LISINOPRIL: warnings: Symptoms have not been relieved by antihistamines in these situations. In these patients, consideration should be given to using a different type of dialysis membrane or[0m
[31ma different class of antihypertensive agent. Anaphylactoid reactions have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption. Hypotension and [0m
[31mRelated Effects Excessive hypotension was rarely seen in uncomplicated hypertensive patients but is a possible consequence of lisinopril use in salt/volume-depleted persons such as those treated [0m
[31mvigorously with diuretics or patients on dialysis. [0m[1;31m([0m[31mSee PRECAUTIONS, Drug Interactions and ADVERSE REACTIONS .[0m[1;31m)[0m[31m Syncope has been reported in [0m[1;31m0.8[0m[31m percent of patients receiving lisinopril and [0m
[31mhydrochlorothiazide tablets. In patients with hypertension receiving lisinopril alone, the incidence of syncope was [0m[1;31m0.1[0m[31m percent. LISINOPRIL: warnings: The overall incidence of syncope may be reduced [0m
[31mby proper titration of the individual components. [0m[1;31m([0m[31mSee PRECAUTIONS, Drug Interactions , ADVERSE REACTIONS and DOSAGE AND ADMINISTRATION .[0m[1;31m)[0m[31m In patients with severe congestive heart failure, with or [0m
[31mwithout associated renal insufficiency, excessive hypotension has been observed and may be associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death. [0m
[31mBecause of the potential fall in blood pressure in these patients, therapy should be started under very close medical supervision. Such patients should be followed closely for the first two weeks of [0m
[31mtreatment and whenever the dose of lisinopril and/or diuretic is increased. Similar considerations apply to patients with ischemic heart or cerebrovascular disease in whom an excessive fall in blood [0m
[31mpressure could result in a myocardial infarction or cerebrovascular accident. LISINOPRIL: warnings: If hypotension occurs, the patient should be placed in supine position and, if necessary, receive an[0m
[31mintravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further doses which usually can be given without difficulty once the blood pressure has increased [0m
[31mafter volume expansion. Neutropenia/Agranulocytosis Another angiotensin-converting enzyme inhibitor, captopril, has been shown to cause agranulocytosis and bone marrow depression, rarely in [0m
[31muncomplicated patients but more frequently in patients with renal impairment, especially if they also have a collagen vascular disease. Available data from clinical trials of lisinopril are [0m
[31minsufficient to show that lisinopril does not cause agranulocytosis at similar rates. Marketing experience has revealed rare cases of neutropenia and bone marrow depression in which a causal [0m
[31mrelationship to lisinopril cannot be excluded. LISINOPRIL: warnings: Periodic monitoring of white blood cell counts in patients with collagen vascular disease and renal disease should be considered. [0m
[31mHepatic Failure Rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice or hepatitis and progresses to fulminant hepatic necrosis, and [0m[1;31m([0m[31msometimes[0m[1;31m)[0m[31m death. The [0m
[31mmechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive [0m
[31mappropriate medical follow-up. Hydrochlorothiazide Thiazides should be used with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects[0m
[31mof the drug may develop in patients with impaired renal function. Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations[0m
[31mof fluid and electrolyte balance may precipitate hepatic coma. LISINOPRIL: warnings: Sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma. The [0m
[31mpossibility of exacerbation or activation of systemic lupus erythematosus has been reported. Lithium generally should not be given with thiazides [0m[1;31m([0m[31msee PRECAUTIONS, Drug Interactions , Lisinopril and [0m
[31mHydrochlorothiazide [0m[1;31m)[0m[31m. Acute Myopia and Secondary Angle-Closure Glaucoma : Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute [0m
[31mangle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can [0m
[31mlead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular [0m
[31mpressure remains uncontrolled.         [0m
[31mSOURCE:LISINOPRIL label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The available information from the LISINOPRIL label does not specifically mention an increased risk of aplastic anemia as an adverse reaction. However, it does list hematologic adverse [0m
[32mreactions such as rare cases of neutropenia, thrombocytopenia, and bone marrow depression. Hemolytic anemia has also been reported, but a causal relationship to lisinopril cannot be excluded. It is [0m
[32mimportant to note that while aplastic anemia is not explicitly mentioned, the occurrence of other hematologic adverse reactions suggests that blood dyscrasias may be a potential risk with lisinopril [0m
[32muse, although the exact frequency or causal relationship is not established.[0m

[32mSOURCE: LISINOPRIL label[0m
[32mEXTRACT_START_END: Hematologic: Rare cases of neutropenia[0m[32m...[0m[32m bone marrow depression have been reported.[0m
*[1m([0morchestrator-aplastic anemia-LISINOPRIL[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The available information from the LISINOPRIL label does not [0m
[34mspecifically mention an increased risk of aplastic anemia as an adverse reaction. However, it does list hematologic adverse reactions such as rare cases of neutropenia, thrombocytopenia, and bone [0m
[34mmarrow depression. Hemolytic anemia has also been reported, but a causal relationship to lisinopril cannot be excluded. It is important to note that while aplastic anemia is not explicitly mentioned, [0m
[34mthe occurrence of other hematologic adverse reactions suggests that blood dyscrasias may be a potential risk with lisinopril use, although the exact frequency or causal relationship is not [0m
[34mestablished.[0m

[34mSOURCE: LISINOPRIL label[0m
[34mEXTRACT_START_END: Hematologic: Rare cases of neutropenia[0m[34m...[0m[34m bone marrow depression have been reported.[0m
 [1m([0morchestrator-aplastic anemia-LISINOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-LISINOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-aplastic anemia-LISINOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does LISINOPRIL increase or decrease the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if LISINOPRIL increases the risk of aplastic anemia."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the LISINOPRIL label does not specifically mention an increased risk of aplastic anemia."[0m[32m,[0m
[32m      [0m[32m"The label does list hematologic adverse reactions such as rare cases of neutropenia, thrombocytopenia, and bone marrow depression. Hemolytic anemia has also been reported, but a causal [0m
[32mrelationship to lisinopril cannot be excluded."[0m[32m,[0m
[32m      [0m[32m"While aplastic anemia is not explicitly mentioned, the occurrence of other hematologic adverse reactions suggests that blood dyscrasias may be a potential risk with lisinopril use, although the[0m
[32mexact frequency or causal relationship is not established."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"LISINOPRIL does not have a specifically established increased risk of aplastic anemia according to the label information. However, it does have hematologic adverse reactions, including [0m
[32mrare cases of neutropenia, thrombocytopenia, and bone marrow depression. Hemolytic anemia has been reported as well, but without a confirmed causal relationship. Therefore, while aplastic anemia is [0m
[32mnot explicitly listed, there may be a potential risk for blood dyscrasias with lisinopril use, but the degree of risk and the causal relationship are not clearly defined."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-LISINOPRIL[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-aplastic anemia-LISINOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-LISINOPRIL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-aplastic anemia-LISINOPRIL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does LISINOPRIL increase or decrease the risk of aplastic anemia?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if LISINOPRIL increases the risk of aplastic anemia."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the LISINOPRIL label does not specifically mention an increased risk of aplastic anemia."[0m[34m,[0m
[34m      [0m[34m"The label does list hematologic adverse reactions such as rare cases of neutropenia, thrombocytopenia, and bone marrow depression. Hemolytic anemia has also been reported, but a causal [0m
[34mrelationship to lisinopril cannot be excluded."[0m[34m,[0m
[34m      [0m[34m"While aplastic anemia is not explicitly mentioned, the occurrence of other hematologic adverse reactions suggests that blood dyscrasias may be a potential risk with lisinopril use, although the[0m
[34mexact frequency or causal relationship is not established."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"LISINOPRIL does not have a specifically established increased risk of aplastic anemia according to the label information. However, it does have hematologic adverse reactions, including [0m
[34mrare cases of neutropenia, thrombocytopenia, and bone marrow depression. Hemolytic anemia has been reported as well, but without a confirmed causal relationship. Therefore, while aplastic anemia is [0m
[34mnot explicitly listed, there may be a potential risk for blood dyscrasias with lisinopril use, but the degree of risk and the causal relationship are not clearly defined."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does LISINOPRIL increase or decrease the risk of aplastic anemia?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if LISINOPRIL increases the risk of aplastic anemia.[0m
[1;31m2[0m[31m. FDAHandler responded that the LISINOPRIL label does not specifically mention an increased risk of aplastic anemia.[0m
[1;31m3[0m[31m. The label does list hematologic adverse reactions such as rare cases of neutropenia, thrombocytopenia, and bone marrow depression. Hemolytic anemia has also been reported, but a causal relationship[0m
[31mto lisinopril cannot be excluded.[0m
[1;31m4[0m[31m. While aplastic anemia is not explicitly mentioned, the occurrence of other hematologic adverse reactions suggests that blood dyscrasias may be a potential risk with lisinopril use, although the [0m
[31mexact frequency or causal relationship is not established.[0m
[31m        -----[0m
[31m        Final answer: LISINOPRIL does not have a specifically established increased risk of aplastic anemia according to the label information. However, it does have hematologic adverse reactions, [0m
[31mincluding rare cases of neutropenia, thrombocytopenia, and bone marrow depression. Hemolytic anemia has been reported as well, but without a confirmed causal relationship. Therefore, while aplastic [0m
[31manemia is not explicitly listed, there may be a potential risk for blood dyscrasias with lisinopril use, but the degree of risk and the causal relationship are not clearly defined.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-aplastic anemia-LISINOPRIL[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-aplastic anemia-LISINOPRIL[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-aplastic anemia-LISINOPRIL[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-aplastic anemia-LISINOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-aplastic anemia-LISINOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe final answer to the question [0m[32m"Does LISINOPRIL increase or decrease the risk of aplastic anemia?"[0m[32m is as follows:[0m

[32mLISINOPRIL does not have a specifically established increased risk of aplastic anemia according to the label information. However, it does have hematologic adverse reactions, including rare cases of [0m
[32mneutropenia, thrombocytopenia, and bone marrow depression. Hemolytic anemia has been reported as well, but without a confirmed causal relationship. Therefore, while aplastic anemia is not explicitly [0m
[32mlisted, there may be a potential risk for blood dyscrasias with lisinopril use, but the degree of risk and the causal relationship are not clearly defined.[0m
